下一代放射治疗法开发商CollimateHealth获得600万欧元种子轮融资，旨在通过微束放射治疗靶向免疫反应-动脉网

A radically new biological approach for cancer patients

D-Pharm 等信源发布 2026-06-16 12:01



可切换为仅中文







CollimateHealth GmbH, a pioneering life sciences start-up for next-generation

CollimateHealth GmbH，一家开创性的下一代生命科学初创企业

radiation therapy

放射治疗

, announced the close of its €6 million

，宣布完成其600万欧元的

seed financing

种子轮融资

round. The round was significantly oversubscribed and supported by renowned life sciences investors including VP Venture Partners, Positron, XISTA Science Ventures, High-Tech

本轮融资获大幅超额认购，并得到包括 VP Venture Partners、Positron、XISTA Science Ventures 和 High-Tech 在内的知名生命科学投资机构的支持。

Gründerfonds (HTGF) and caesar. The company expects to use its technology in patients for the first time within the next three years.

Gründerfonds (HTGF) 和 caesar。该公司预计将在未来三年内首次将技术应用于患者。

Microbeam radiation therapy – a radically new biological approach to cancer treatment

微束放射治疗——一种全新的癌症治疗生物学方法

CollimateHealth has developed a clinically scalable microbeam radiation therapy designed to revolutionise the way cancer is treated. Current radiation therapy typically relies on broad, low-dose beams and causes significant side effects. By contrast, microbeam radiation therapy uses bundled, extremely narrow beams in the micrometre range at a much higher dose..

CollimateHealth 公司开发了一种具有临床可扩展性的微束放射疗法，旨在彻底变革癌症治疗方式。目前的放射疗法通常依赖宽泛的低剂量光束，并会导致显著的副作用。相比之下，微束放射疗法使用成束的、微米级极窄光束，且剂量高得多。

European startups at the forefront of the fight against cancer

站在抗癌前沿的欧洲初创企业

With nearly 1,500 entities, Europe hosts a larger number of cancer-related startups than the US

欧洲拥有近1500家实体，其癌症相关初创企业的数量多于美国。

Read news

阅读新闻

Tumours treated with microbeams undergo an especially intense form of cell death that increases antigen presentation and thereby triggers an immune response against cancer cells – even beyond the primarily irradiated area. In addition, the temporary channels created by microbeam radiation therapy improve the delivery of therapeutics into tumour tissue, creating synergies with both chemotherapy and immunotherapy..

经微束治疗的肿瘤会经历一种特别强烈的细胞死亡形式，这种死亡方式可增强抗原呈递，从而引发针对癌细胞的免疫反应——其作用范围甚至超出主要照射区域。此外，微束放射疗法产生的临时通道改善了治疗药物向肿瘤组织的递送，与化疗和免疫疗法均产生协同效应。

Dr Hans Maria Heÿn, co-founder and CEO of CollimateHealth: “What Stefan Bartzsch, Johanna Winter and the interdisciplinary team have achieved through years of academic research is truly exceptional. Shrinking the medical beamline of a synchrotron into a system with a footprint of less than 10 square metres is a genuine deep-tech moonshot with the potential to fundamentally change cancer treatment.”.

CollimateHealth 联合创始人兼首席执行官汉斯·玛丽亚·海恩博士表示：“斯特凡·巴尔奇施、约翰娜·温特以及这个跨学科团队通过多年的学术研究取得的成就确实非凡。将同步加速器的医用光束线缩小至占地面积不足10平方米的系统，是一项真正的深科技‘登月式’突破，有望从根本上改变癌症治疗方式。”

The €6 million seed financing will be used to build the first clinical prototype and generate preclinical data intended to pave the way through future regulatory approval processes. The company’s goal is to begin treating its first patients with microbeam radiation therapy by the end of 2028.

这笔600万欧元的种子轮融资将用于构建首个临床原型并生成临床前数据，旨在为未来的监管审批流程铺平道路。该公司的目标是在2028年底前开始使用微束放射疗法治疗首批患者。

CollimateHealth – an example of the disruptive power of outstanding science

CollimateHealth——卓越科学颠覆性力量的典范

CollimateHealth was launched as a venture-build project by VP Venture Partners and co-founded by Prof. Dr Stefan Bartzsch, Chief Scientific Officer, Dr Johanna Winter, Chief Technology Officer, and Dr Hans Maria Heÿn, Chief Executive Officer. Bartzsch, Winter and the technical team have spent almost a decade developing the company’s core technology, microbeam radiation therapy.

CollimateHealth 是由 VP Venture Partners 发起的一项创业孵化项目，由首席科学官 Stefan Bartzsch 教授、首席技术官 Johanna Winter 博士以及首席执行官 Hans Maria Heÿn 博士联合创立。Bartzsch、Winter 及其技术团队耗时近十年，开发了公司的核心技术——微束放射疗法。

Heÿn brings many years of entrepreneurial experience in building and leading deep-tech life sciences companies. A technically experienced team has supported the founders from the outset with a focus on bringing the platform into clinical use..

Heÿn 在构建和领导深科技生命科学公司方面拥有多年的创业经验。一支具备深厚技术经验的团队从一开始就为创始人提供支持，专注于推动该平台进入临床应用。

CollimateHealth has been supported by UnternehmerTUM, the TUM Venture Lab Healthcare, BioM, BayStartUP and Medical Valley, and has received numerous innovation awards, including a Falling Walls Award in 2025 and the MedTech Ideator Award at Best of Biotech in Vienna in 2025. The underlying technology was further developed in collaboration with leading academic and clinical institutions, including the Technical University of Munich (TUM), TUM University Hospital rechts der Isar, Johannes Gutenberg University Mainz, Helmholtz Institute Mainz, Forschungszentrum Jülich, the Institute of Cancer Research and The Royal Marsden Hospital in London..

CollimateHealth 得到了 UnternehmerTUM、TUM 创业实验室医疗健康部门（TUM Venture Lab Healthcare）、BioM、BayStartUP 以及 Medical Valley 的支持，并荣获多项创新奖项，包括 2025 年的“推倒柏林墙”奖（Falling Walls Award）以及 2025 年维也纳“最佳生物技术”（Best of Biotech）活动中的 MedTech Ideator 奖。其底层技术是与领先的学术和临床机构合作进一步开发的，这些机构包括慕尼黑工业大学（TUM）、慕尼黑工业大学右伊萨尔河大学医院、美因茨约翰内斯·古腾堡大学、美因茨亥姆霍兹研究所、于利希研究中心、伦敦癌症研究所以及皇家马斯登医院。

Dr. Valentin Piëch, Managing Director of VP Venture Partners: “What makes this technology so compelling is not only its potential to redefine radiation oncology, but also the opportunities it may unlock in combination with immunotherapy and other cancer treatments.”

VP Venture Partners 总经理瓦伦丁·皮耶赫博士表示：“这项技术之所以如此引人注目，不仅在于其有望重新定义放射肿瘤学，还在于它与免疫疗法及其他癌症治疗手段结合时可能开启的机遇。”

Joseph Peeraer, Founding Partner at Positron: “CollimateHealth demonstrates the disruptive power of outstanding science. We believe this microbeam platform has the potential to become an important future building block in radiation oncology and in the broader fight against cancer.”

Positron 创始合伙人约瑟夫·皮雷尔表示：“CollimateHealth 展现了卓越科学的颠覆性力量。我们相信，这一微束平台有望成为放射肿瘤学领域以及更广泛的抗癌斗争中的重要未来基石。”

Stephan Huber, Venture Partner at XISTA Science Ventures: “CollimateHealth combines world-class, cutting-edge science with the raw ambition needed to scale a global deep-tech company that dares to take on decades old paradigms in what is a central pillar of cancer treatment. Their technology has the potential to move the needle for millions of very sick patients worldwide.”.

XISTA Science Ventures 的风险合伙人 Stephan Huber 表示：“CollimateHealth 将世界一流的尖端科学与打造全球性深科技企业所需的雄心壮志相结合，敢于挑战癌症治疗这一核心领域中存在数十年的传统范式。他们的技术有望为全球数百万重症患者带来实质性的改善。”

Dr. Jan Engels, Senior Investment Manager at HTGF: “CollimateHealth is exactly the kind of deep-tech venture HTGF was founded to support: a world-class scientific team translating years of rigorous research into a technology that could genuinely change outcomes for cancer patients. What excites us most is not just the physics — it’s the clinical ambition.

HTGF高级投资经理Jan Engels博士表示：“CollimateHealth正是HTGF创立之初旨在支持的深科技创业公司典范：一个世界级的科学团队，将多年的严谨研究成果转化为一种能够切实改善癌症患者预后的技术。最令我们振奋的不仅是其物理原理，更是其临床抱负。”

The team has a clear path to first-patient use, and we are proud to back them on that journey.”.

该团队拥有清晰的首例患者使用路径，我们很自豪能在这段旅程中支持他们。

https://www.bionity.com/en/news/1188939/a-radically-new-biological-approach-for-cancer-patients.html

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery

QUANTRO Therapeutics在转录组药物发现领域取得突破性进展

First successful simultaneous 10-target multiplex-screening

首次成功实现10个靶标的同步多重筛查

Read news

阅读新闻